Ausgabe 3/2011
Inhalt (13 Artikel)
Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation
Bo Hong, Vivian W. Y. Lui, Edwin P. Hui, Margaret H. L. Ng, Suk-Hang Cheng, Fion L. Sung, Chi-Man Tsang, Sai-Wah Tsao, Anthony Tak-Cheung Chan
Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells
Jana Vobořilová, Vlasta Němcová-Fürstová, Jitka Neubauerová, Iwao Ojima, Ilaria Zanardi, Ivan Gut, Jan Kovář
Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents
Elisabeth Miot-Noirault, Bastien Reux, Eric Debiton, Jean-Claude Madelmont, Jean-Michel Chezal, Pascal Coudert, Valérie Weber
Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents
Asama Mukherjee, Suva Hazra, Sushanta Dutta, Shanmugavel Muthiah, Dilip Manikrao Mondhe, Parduman Raj Sharma, Shashank Kumar Singh, Ajit Kumar Saxena, Gulam Nabi Qazi, Utpal Sanyal
Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan
Sergio Cafaggi, Eleonora Russo, Rossana Stefani, Brunella Parodi, Gabriele Caviglioli, Greta Sillo, Angela Bisio, Cinzia Aiello, Maurizio Viale
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
Andries M. Bergman, Auke D. Adema, Jan Balzarini, Skjalg Bruheim, Iduna Fichtner, Paul Noordhuis, Øystein Fodstad, Finn Myhren, Marit L. Sandvold, Hans R. Hendriks, Godefridus J. Peters
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
Howard A. Burris III, Suzanne F. Jones, Daphne D. Williams, Steven J. Kathman, Jeffrey P. Hodge, Lini Pandite, Peter T. C. Ho, Scott A. Boerner, Patricia LoRusso
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard, Charles Erlichman, David O. Toft, Rui Qin, Bridget A. Stensgard, Sara Felten, Cynthia Ten Eyck, Gretchen Batzel, S. Percy Ivy, Paul Haluska
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
Simon Pacey, Mark J. Ratain, Keith T. Flaherty, Stanley B. Kaye, Lisa Cupit, Eric K. Rowinsky, Chenghua Xia, Peter J. O’Dwyer, I. R. Judson
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
Evan M. Hersh, Steven J. O’Day, John Powderly, Khuda D. Khan, Anna C. Pavlick, Lee D. Cranmer, Wolfram E. Samlowski, Geoffrey M. Nichol, Michael J. Yellin, Jeffrey S. Weber
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
Hai T. Tran, Ralph G. Zinner, George R. Blumenschein Jr., Yun W. Oh, Vassiliki A. Papadimitrakopoulou, Edward S. Kim, Charles Lu, Mubashira Malik, Bert L. Lum, Roy S. Herbst
ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof
Sarah Schott, Markus Wallwiener, Beate Kootz, Harald Seeger, Tanja Fehm, Hans Neubauer
A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe
Oliver Riesterer, Fumihiko Matsumoto, Li Wang, Jessica Pickett, David Molkentine, Uma Giri, Luka Milas, Uma Raju